Skip to main content
. 2022 Sep;33(9):1767–1777. doi: 10.1681/ASN.2022020135

Table 1.

Baseline characteristics of the participants initiating rosuvastatin or atorvastatin before applying IPTW

Characteristic Rosuvastatin Initiators Atorvastatin Initiators Standardized Mean Differences (%)
No. of cohorts 40 40
No. of participants 152,101 795,799
Age, mean (SD), yr 60.6 (11.7) 60.0 (12.2) 5.37
Women, n (%) 77,230 (50.8) 373,794 (47.0) 7.62
Race/ethnicity, n (%)
 Black 12,099 (8.0) 80,224 (10.1) −7.17
 Hispanic 6006 (3.9) 31,287 (3.9) 0.09
 White 125,853 (82.7) 641,237 (80.6) 5.51
 Othera 8143 (5.4) 43,051 (5.4) −0.25
eGFR, mean (SD), ml/min per 1.73 m2 80.5 (18.9) 81.7 (19.4) −6.17
eGFR category, n (%)
 ≥60 ml/min per 1.73 m2 130,506 (85.8) 687,461 (86.4) −1.70
 30–59 ml/min per 1.73 m2 20,427 (13.4) 102,392 (12.9) 1.68
 <30 ml/min per 1.73 m2 1168 (0.8) 5946 (0.7) 0.24
BMI, mean (SD), kg/m2 30.9 (6.5) 31.3 (6.9) −5.45
Smoking, n (%)
 Current 9620 (6.3) 63,557 (8.0) −6.23
 Former 25,142 (16.5) 137,723 (17.3) −2.06
 Never 117,339 (77.1) 594,519 (74.7) 5.64
SBP, mean (SD), mm Hg 128.1 (16.0) 129.1 (16.5) −6.08
Serum K, mean (SD), mmol/L 4.31 (0.41) 4.28 (0.41) 6.92
Comorbidities, n (%)
 Diabetes 42,904 (28.2) 236,744 (29.7) −3.38
 Hypertension 100,712 (66.2) 535,710 (67.3) −2.35
 Coronary artery disease 39,031 (25.7) 185,365 (23.3) 5.57
 Cerebrovascular disease 14,506 (9.5) 84,096 (10.6) −3.38
 Heart failure 8156 (5.4) 51,274 (6.4) −4.46
 Hypothyroidism 26,445 (17.4) 120,861 (15.2) 6.07
Concomitant medications, n (%)
 ACE inhibitors 28,348 (18.6) 182,927 (23.0) −10.46
 ARBs 18,941 (12.5) 81,497 (10.2) 7.19
 Aldosterone antagonists 2022 (1.3) 11,702 (1.5) −1.18
 Other HTN medications 49,370 (32.5) 278,790 (35.0) −5.41
 SGLT2 inhibitors 1594 (1.0) 6259 (0.8) 2.88
 DPP4 inhibitors 3189 (2.1) 13,004 (1.6) 3.57
 GLP1RAs 1731 (1.1) 6883 (0.9) 2.88
 Other oral DM medications 19,859 (13.1) 123,491 (15.5) −6.87
 Insulin 6236 (4.1) 35,886 (4.5) −1.99
 DOACs 1715 (1.1) 11,651 (1.5) −2.85
 Warfarin 2481 (1.6) 15,881 (2.0) −2.64
 Antiplatelets 7879 (5.2) 50,054 (6.3) −4.63
 Cyclosporine 143 (0.1) 474 (0.1) 1.35
 Itraconazole 28 (0.0) 152 (0.0) −0.05
 Clarithromycin 105 (0.1) 435 (0.1) 0.60
 Protease inhibitors 76 (0.0) 323 (0.0) 0.46
 Fibrates 5605 (3.7) 18,874 (2.4) 8.28
 Niacin 1422 (0.9) 3241 (0.4) 7.54
 PCSK9 inhibitor 100 (0.1%) 59 (0.0) 4.50
 Ezetimibe 3850 (2.5) 7251 (0.9) 15.08
Baseline year, n (%)
 2011 12,993 (8.5) 23,568 (3.0) 29.15
 2012 14,013 (9.2) 47,819 (6.0) 12.99
 2013 12,756 (8.4) 65,200 (8.2) 0.70
 2014 15,270 (10.0) 94,762 (11.9) −5.83
 2015 14,744 (9.7) 116,337 (14.6) −14.29
 2016 14,646 (9.6) 120,628 (15.2) −15.83
 2017 18,307 (12.0) 115,576 (14.5) −7.14
 2018 21,633 (14.2) 105,943 (13.3) 2.67
 2019 27,739 (18.2) 105,966 (13.3) 14.16
Total cholesterolb
 Missing, n (%) 42,028 (27.6) 219,096 (27.5)
 Mean (SD), mmol/L 4.9 (1.0) 5.0 (1.0) −7.16
LDL cholesterolb
 Missing 32,169 (21.1) 164,774 (20.7)
 Mean (SD), mmol/L 3.5 (1.0) 3.5 (1.0) 2.61

BMI, body mass index; SBP, systolic BP; ACE inhibitors, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; SGLT2 inhibitors, sodium-glucose cotransporter 2 inhibitors; DPP4 inhibitors, dipeptidyl peptidase-4 inhibitor; GLP1RAs, glucagon-like peptide 1 receptor agonists; DOACs, direct oral anticoagulants; PCSK9 inhibitors, proprotein convertase subtilisin/kexin type 9 inhibitors.

a

Other includes Asian patients and patients with unknown race/ethnicity.

b

Only among patients with values available. Cholesterol level was not included in the propensity score model.